<div id="readability-page-1"><div><h2>Context for Shanghai Junshi Biosciences after recent share performance</h2> <p>Shanghai Junshi Biosciences (SEHK:1877) has seen mixed share performance recently, with a small gain over the past week but declines over the past month and past 3 months, drawing attention to how its fundamentals line up.</p> <p>For investors tracking the stock longer term, the shares show a negative total return over 3 and 5 years, while the 1 year total return is positive. This can make current pricing and expectations especially important to understand.</p> <p>See our latest analysis for Shanghai Junshi Biosciences.</p> <p>The recent 7 day share price return of 3.78% contrasts with a 90 day share price decline of 15.79%, suggesting momentum has cooled even as the 1 year total shareholder return of 38.54% remains firmly positive.</p> <p>If this mix of gains and pullbacks has you thinking about where growth stories could come from next, it might be worth scanning our screener for 123 healthcare AI stocks as a fresh set of ideas.</p> <p>With Shanghai Junshi Biosciences trading at HK$20.06 and some metrics suggesting a possible discount to estimated value, the key question is whether this represents a genuine buying opportunity or if the market already prices in future growth.</p> <h2>Preferred Price-to-Sales Multiple of 7.3x: Is it justified?</h2> <p>On a P/S basis, Shanghai Junshi Biosciences at HK$20.06 screens as undervalued compared with both peers and the wider Hong Kong Biotechs industry.</p> <p>The P/S ratio looks at how much investors are paying for each dollar of revenue, which can be helpful for a company that is still loss making. With Shanghai Junshi Biosciences currently unprofitable and reporting a net loss of HK$874.39m on revenue of HK$2,498.42m, focusing on sales rather than earnings gives a cleaner read on how the market is valuing its commercial progress.</p> <p>Right now, the company trades on a P/S of 7.3x, which is below the peer average of 9.6x and also below the Hong Kong Biotechs industry average of 13.4x. The SWS fair P/S estimate of 13.4x is materially higher than the current multiple, which suggests the market is pricing its revenue at a lower level than that fair ratio could support.</p> <p>Explore the SWS fair ratio for Shanghai Junshi Biosciences</p> <p><strong>Result: Price-to-Sales of 7.3x (UNDERVALUED)</strong></p> <p>However, the story could shift if revenue growth of 23.15% slows sharply, or if the HK$874.39m net loss widens and drags on investor confidence.</p> <p>Find out about the key risks to this Shanghai Junshi Biosciences narrative.</p> <h2>Another view from the SWS DCF model</h2> <p>The SWS DCF model points to an estimated value of HK$80.46 per share for Shanghai Junshi Biosciences, versus the current HK$20.06 price. This also screens as undervalued on this approach. If both revenue based multiples and cash flow estimates look generous, what could the market be worried about?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23a01872-57a3-4018-8a4d-cab1cf8bed14/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTE1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23a01872-57a3-4018-8a4d-cab1cf8bed14/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTE1"/><figcaption>1877 Discounted Cash Flow as at Mar 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Junshi Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 229 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Given this mix of concerns and positives, do you want to see the data for yourself and decide quickly where you stand? Our breakdown highlights 4 key rewards and 1 important warning sign so you can weigh both sides in one place.</p> <h2>Looking for more investment ideas?</h2> <p>If this company has sharpened your thinking, do not stop here. The screener can surface other opportunities that might fit your approach even better.</p> <ul> <li>Spot potential mispricings early by scanning our list of 229 high quality undervalued stocks that combine appealing valuations with solid fundamentals.</li> <li>Prioritise resilience by reviewing 296 resilient stocks with low risk scores that stand out on our risk scoring and may suit a steadier portfolio core.</li> <li>Hunt for underfollowed opportunities by checking our screener containing 581 high quality undiscovered gems that have strong numbers yet limited market attention so far.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

688180

01877

513700

<p>Shanghai Junshi Biosciences (SEHK: 1877) has experienced mixed share performance, with a recent 3.78% gain over the past week but a 15.79% decline over the last 90 days. The company shows a positive 1-year total return of 38.54%, yet negative returns over 3 and 5 years. Currently trading at HK$20.06, it appears undervalued with a P/S ratio of 7.3x compared to industry averages. A DCF model estimates a fair value of HK$80.46 per share, indicating potential growth opportunities despite existing risks.</p>

Shanghai Junshi Biosciences SEHK 1877 Valuation After Mixed Recent Share Performance And DCF Upside Potential